This grant supports research and development of innovative antimicrobial agents targeting drug-resistant bacterial and fungal pathogens. Projects should aim to provide new therapies to treat antimicrobial resistant infections, contributing to public health and reducing the disease burden of AMR. The focus includes developing antibacterial and antifungal agents (including antibody-based therapies) that meet World Health Organization (WHO) innovation criteria: new chemical class, new target, new mode of action, or no evidence of cross-resistance. Projects may not include phage therapies. Accelerating human trial testing and engaging regulatory bodies is expected. Participation of SMEs and international partners, and consideration of biological and social factors, is encouraged.
| Agency | HORIZON (EU) |
|---|---|
| Region | EUUSAother |
| Country | N/A |
| Legal form | Company, NGO, Government organization, Other |
| Start date | 10 Feb 2027 |
| End date | 13 Apr 2027 |
| Max funding | 8,000,000 – 10,000,000 EUR per grant |
| Budget | 44,200,000 EUR in 2027 for this topic |
| Coverage | Eligible legal entities from EU and countries associated with Horizon Europe can receive funding. US entities are eligible to receive EU funds. See Horizon Europe rules for further details. |